Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F, Loriot Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: combarel d. Clin Cancer Res. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.
Breast cancer survivors' opinion on personalizing endocrine therapy and developing informative tools.
Rassy E, Benvenuti C, Akla S, Di Meglio A, Martin E, Havas J, Rieutord A, Combarel D, Fasse L, Scotté F, Guéroult Accolas L, Jacob G, Bergougnoux A, Delaloge S, Vaz-Luis I, Pistilli B. Rassy E, et al. Among authors: combarel d. NPJ Breast Cancer. 2024 Jun 17;10(1):48. doi: 10.1038/s41523-024-00655-1. NPJ Breast Cancer. 2024. PMID: 38886406 Free PMC article.
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.
Ferrer F, Tetu P, Dousset L, Lebbe C, Ciccolini J, Combarel D, Meyer N, Paci A, Bouchet S. Ferrer F, et al. Among authors: combarel d. Crit Rev Oncol Hematol. 2024 Aug;200:104385. doi: 10.1016/j.critrevonc.2024.104385. Epub 2024 May 27. Crit Rev Oncol Hematol. 2024. PMID: 38810843 Review.
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I.
Combarel D, Dousset L, Bouchet S, Ferrer F, Tetu P, Lebbe C, Ciccolini J, Meyer N, Paci A. Combarel D, et al. Crit Rev Oncol Hematol. 2024 Jul;199:104384. doi: 10.1016/j.critrevonc.2024.104384. Epub 2024 May 16. Crit Rev Oncol Hematol. 2024. PMID: 38762217 Review.
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B, Xu-Vuilard A, Jouinot A, Puisset F, Combarel D, Huillard O, Le Louedec F, Thomas F, Teixeira M, Flippot R, Mourey L, Albiges L, Pudlarz T, Joly C, Tournigand C, Chauvin J, Puszkiel A, Chatelut E, Decleves X, Vidal M, Goldwasser F, Oudard S, Medioni J, Vano YA. Blanchet B, et al. Among authors: combarel d. Br J Cancer. 2024 Apr;130(6):961-969. doi: 10.1038/s41416-024-02585-y. Epub 2024 Jan 25. Br J Cancer. 2024. PMID: 38272963
20 results